Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
64,565,348
-
Share change
-
+5,698,745
-
Total reported value
-
$2,559,511,066
-
Put/Call ratio
-
126%
-
Price per share
-
$39.64
-
Number of holders
-
178
-
Value change
-
+$355,521,959
-
Number of buys
-
128
-
Number of sells
-
54
Institutional Holders of ALPINE IMMUNE SCIENCES INC - COM (ALPN) as of Q1 2024
As of 31 Mar 2024,
ALPINE IMMUNE SCIENCES INC - COM (ALPN) was held by
178 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
64,565,348 shares.
The largest 10 holders included
Decheng Capital LLC, Avoro Capital Advisors LLC, BlackRock Inc., Frazier Life Sciences Management, L.P., PRICE T ROWE ASSOCIATES INC /MD/, STATE STREET CORP, VANGUARD GROUP INC, Cormorant Asset Management, LP, ORBIMED ADVISORS LLC, and Lynx1 Capital Management LP.
This page lists
178
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.